drugset / Trial / NCT06422039

Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects

NCT06422039

Phase 1 Completed 24 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.

Timeline

Start
2024-05-23
Primary completion
2024-08-06
Completion
2024-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-7535 Small molecule